Abbott Launches TriClip Minimally Invasive Tricuspid Regurgitation Therapy in India

Abbott's entry into the Indian market with TriClip shifts the clinical pathway for tricuspid regurgitation from open surgical intervention to a catheter-based repair option, with direct implications for cardiac device procurement, clinical protocol alignment, and post-market surveillance obligations under India's medical device regulatory framework.

Tricuspid regurgitation is a structural heart condition frequently underdiagnosed in the Indian patient population and closely associated with progressive heart failure. The condition has historically been managed conservatively or addressed through open-chest surgery, leaving a significant treatment gap for patients deemed high-risk for conventional procedures. TriClip addresses that gap by enabling percutaneous edge-to-edge repair of the tricuspid valve, reducing regurgitation without cardiopulmonary bypass.

For hospital device committees and procurement leads, the launch introduces a new category of structural heart intervention requiring dedicated catheterization lab infrastructure, trained interventional cardiology teams, and defined patient selection criteria. Institutions integrating TriClip into their cardiac programs will need to establish clinical governance pathways covering operator credentialing, patient screening protocols, and adverse event reporting aligned with CDSCO post-market requirements for Class C and D medical devices.

Abbott's commercial rollout in India follows the device's established use in markets including the United States and the European Union, where real-world registry data on procedural outcomes and durability have been accumulating. That evidence base will be relevant to Indian clinical teams building internal review board submissions and to quality leads responsible for vendor qualification and incoming device inspection under applicable standards.

The supply-chain read is straightforward: TriClip is a single-use, implantable device requiring cold-chain-compatible logistics, controlled storage conditions, and traceability documentation from import through implantation, all of which fall within the scope of India's Medical Devices Rules, 2017.

Measurable adoption rates across India's tier-one cardiac centers over the next 12 to 24 months will serve as the clearest indicator of whether the procedural infrastructure and regulatory alignment required for sustainable TriClip deployment are achievable at scale.

Source: Media4Growth via Indian Pharma Post, 10 May 2026.